8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $605M | $190M | 59.9% | 17.9% | 40.2% | 17.8% | $134M | — | $489M |
| 2024 | $442M | $36M | 59.4% | 8.5% | 15.5% | 4.4% | -$81M | — | $337M |
| 2023 | $242M | -$25M | 63.8% | -11.9% | -18.2% | -3.5% | -$165M | — | $395M |
| 2022 | $93M | -$36M | 69.8% | -33.6% | -19.3% | -13.1% | -$58M | $59M | $202M |
| 2021 | $30M | -$44M | 69.9% | -130.3% | -65.1% | -32.8% | -$32M | $35M | $26M |
| 2020 | $26M | -$29M | 64.9% | -102.9% | -27.7% | -18.9% | -$31M | $35M | $25M |
| 2019 | $24M | -$34M | 58.7% | -125.4% | -61.4% | -31.9% | -$32M | $34M | $21M |
| 2018 | $13M | -$24M | 44.1% | -155.5% | 12.4% | -56.4% | -$26M | $34M | $21M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Mar '26 | $174M | $7M | 58.2% | 7.6% | 1.5% | 0.5% | -$12M | — | $480M |
| Dec '25 | $161M | $105M | 58.1% | 13.2% | 22.3% | 9.9% | $19M | — | $489M |
| Sep '25 | $144M | $24M | 58.8% | 16.2% | 6.8% | 2.6% | $62M | — | $467M |
| Jun '25 | $157M | $35M | 61.4% | 23.2% | 11.0% | 3.9% | $83M | — | $401M |
| Mar '25 | $144M | $26M | 61.5% | 19.1% | 9.6% | 3.1% | -$30M | — | $311M |
| Dec '24 | $122M | $7M | 59.2% | 7.1% | 3.0% | 0.9% | $6M | — | $337M |
| Sep '24 | $109M | $4M | 55.9% | 3.6% | 2.0% | 0.5% | -$41M | — | $331M |
| Jun '24 | $114M | $12M | 60.6% | 10.9% | 6.4% | 1.6% | $2M | — | $363M |
| Mar '24 | $97M | $12M | 61.9% | 12.8% | 7.6% | 1.7% | -$48M | — | $351M |
| Dec '23 | $81M | $4M | 59.0% | 3.2% | 2.9% | 0.6% | -$34M | — | $395M |
| Sep '23 | $66M | -$25M | 61.2% | -42.7% | -20.1% | -3.7% | -$115M | — | $428M |
| Jun '23 | $52M | -$1M | 70.0% | -1.7% | -0.7% | -0.1% | -$7M | — | $583M |
| Mar '23 | $42M | -$3M | 69.2% | -5.0% | -1.4% | -0.9% | -$10M | $59M | $196M |
| Dec '22 | $31M | -$7M | 66.0% | -21.6% | -3.6% | -2.4% | -$7M | $59M | $202M |
| Sep '22 | $26M | -$7M | 70.5% | -21.6% | -4.0% | -2.7% | -$17M | $59M | $205M |
| Jun '22 | $21M | -$12M | 69.9% | -47.5% | -22.6% | -9.8% | -$13M | $35M | $31M |
| Mar '22 | $16M | -$11M | 76.2% | -59.0% | -17.6% | -8.5% | -$20M | $35M | $18M |
| Dec '21 | $10M | -$13M | 72.3% | -117.2% | -18.6% | -9.4% | -$10M | $35M | $26M |
| Sep '21 | $5M | -$13M | 70.3% | -218.3% | -16.5% | -9.9% | -$9M | $35M | $23M |
| Jun '21 | $8M | -$11M | 68.4% | -120.8% | -12.0% | -7.6% | -$6M | $35M | $26M |
How the market has priced TMDX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Transmedics Group, Inc.'s revenue has grown 88.2% per year. These are computed facts, not advice.
As of FY2025, Transmedics Group, Inc. reported — of total debt against $489M of cash; operating income covered interest expense 7.9×.
In FY2025, gross margin was 59.9%, operating margin 17.9%, and net margin 31.4%.
As of Sep '26, Transmedics Group, Inc. traded at a price-to-earnings ratio of about 15.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.